探讨重组人促红细胞生长素在急性脑缺血性脑卒中患者的临床应用前景  

Objective to Investigate the Clinical Application of Recombinant Human Erythropoietin in Patients with Acute Cerebral Ischemic Stroke

作　　者：薛炬君[1] 陈曦[1] 

机构地区：[1]黑龙江省医院老年神经内科,黑龙江哈尔滨150036

出　　处：《中外医疗》2016年第17期30-31,共2页China & Foreign Medical Treatment

摘　　要：目的分析急性缺血性脑卒中患者实施重组人促红细胞生成素治疗方案的治疗效果。方法随机收集2015年4—2015年11月于该院接受治疗的脑梗死患者50例,治疗组25例应用重组促红细胞生成素,对照组25例应用生理盐水,观察两组患者的NIHSS评分、血清NSE、IL-6水平。结果治疗组治疗前与治疗四周后NIHSS量表评分(10.28±1.74),(8.35±3.09);对照组治疗前与治疗四周后NIHSS量表评分为(10.11±1.89),(9.01±2.87)。治疗组NIHSS量表评分改善程度略高于对照组。梗死面积变化治疗组略好于对照组。NSE水平及血清IL-6水平在治疗后均较入院时降低,但治疗组要优于对照组。差异有统计学意义。结论对患有急性缺血性脑卒中患者实施重组人促红细胞生成素治疗方案可以一定程度提高治疗效果,并有效保护患者神经功能。Objective To analyze the therapeutic effect of recombinant human erythropoietin therapy in patients with acute ischemic stroke. Methods Random selection collect April 2015 to November 2015 in our hospital received the treatment of50 cases of patients with cerebral infarction, treatment group（n = 25） application of recombinant erythropoietin, control group, 25 patients were treated with normal saline, observe two groups NIHSS score, serum NSE and IL-6 levels. Results Before and after treatment, the treatment group was treated with NIHSS scale score（10.28±1.74）,（8.35±3.09）; the control group before treatment and after treatment, the NIHSS scale score was（10.11 ±1.89）,（9.01 ±2.87）. The improvement degree of NIHSS in treatment group was slightly higher than that in control group. Treatment group was slightly better than the control group. NSE levels and serum IL- 6 levels were lower in the treatment group than in the hospital, but the treatment group was better than the control group. Conclusion The recombinant human erythropoietin in patients with acute ischemic stroke was performed.

关 键 词：重组人促红细胞生成素 急性缺血性脑卒中 应用前景 

分 类 号：R4[医药卫生—临床医学]